Cargando…
Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease
The presence of insoluble aggregates of amyloid β (Aβ) in the form of neuritic plaques (NPs) is one of the main features that define Alzheimer’s disease. Studies have suggested that the accumulation of these peptides in the brain significantly contributes to extensive neuronal loss. Furthermore, the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603563/ https://www.ncbi.nlm.nih.gov/pubmed/36292947 http://dx.doi.org/10.3390/ijms232012092 |
_version_ | 1784817584660545536 |
---|---|
author | Campos-Peña, Victoria Pichardo-Rojas, Pavel Sánchez-Barbosa, Talía Ortíz-Islas, Emma Rodríguez-Pérez, Citlali Ekaterina Montes, Pedro Ramos-Palacios, Gerardo Silva-Adaya, Daniela Valencia-Quintana, Rafael Cerna-Cortes, Jorge Francisco Toral-Rios, Danira |
author_facet | Campos-Peña, Victoria Pichardo-Rojas, Pavel Sánchez-Barbosa, Talía Ortíz-Islas, Emma Rodríguez-Pérez, Citlali Ekaterina Montes, Pedro Ramos-Palacios, Gerardo Silva-Adaya, Daniela Valencia-Quintana, Rafael Cerna-Cortes, Jorge Francisco Toral-Rios, Danira |
author_sort | Campos-Peña, Victoria |
collection | PubMed |
description | The presence of insoluble aggregates of amyloid β (Aβ) in the form of neuritic plaques (NPs) is one of the main features that define Alzheimer’s disease. Studies have suggested that the accumulation of these peptides in the brain significantly contributes to extensive neuronal loss. Furthermore, the content and distribution of cholesterol in the membrane have been shown to have an important effect on the production and subsequent accumulation of Aβ peptides in the plasma membrane, contributing to dysfunction and neuronal death. The monomeric forms of these membrane-bound peptides undergo several conformational changes, ranging from oligomeric forms to beta-sheet structures, each presenting different levels of toxicity. Aβ peptides can be internalized by particular receptors and trigger changes from Tau phosphorylation to alterations in cognitive function, through dysfunction of the cholinergic system. The goal of this review is to summarize the current knowledge on the role of lipids in Alzheimer’s disease and their relationship with the basal cholinergic system, as well as potential disease-modifying therapies. |
format | Online Article Text |
id | pubmed-9603563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96035632022-10-27 Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease Campos-Peña, Victoria Pichardo-Rojas, Pavel Sánchez-Barbosa, Talía Ortíz-Islas, Emma Rodríguez-Pérez, Citlali Ekaterina Montes, Pedro Ramos-Palacios, Gerardo Silva-Adaya, Daniela Valencia-Quintana, Rafael Cerna-Cortes, Jorge Francisco Toral-Rios, Danira Int J Mol Sci Review The presence of insoluble aggregates of amyloid β (Aβ) in the form of neuritic plaques (NPs) is one of the main features that define Alzheimer’s disease. Studies have suggested that the accumulation of these peptides in the brain significantly contributes to extensive neuronal loss. Furthermore, the content and distribution of cholesterol in the membrane have been shown to have an important effect on the production and subsequent accumulation of Aβ peptides in the plasma membrane, contributing to dysfunction and neuronal death. The monomeric forms of these membrane-bound peptides undergo several conformational changes, ranging from oligomeric forms to beta-sheet structures, each presenting different levels of toxicity. Aβ peptides can be internalized by particular receptors and trigger changes from Tau phosphorylation to alterations in cognitive function, through dysfunction of the cholinergic system. The goal of this review is to summarize the current knowledge on the role of lipids in Alzheimer’s disease and their relationship with the basal cholinergic system, as well as potential disease-modifying therapies. MDPI 2022-10-11 /pmc/articles/PMC9603563/ /pubmed/36292947 http://dx.doi.org/10.3390/ijms232012092 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Campos-Peña, Victoria Pichardo-Rojas, Pavel Sánchez-Barbosa, Talía Ortíz-Islas, Emma Rodríguez-Pérez, Citlali Ekaterina Montes, Pedro Ramos-Palacios, Gerardo Silva-Adaya, Daniela Valencia-Quintana, Rafael Cerna-Cortes, Jorge Francisco Toral-Rios, Danira Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease |
title | Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease |
title_full | Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease |
title_fullStr | Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease |
title_full_unstemmed | Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease |
title_short | Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease |
title_sort | amyloid β, lipid metabolism, basal cholinergic system, and therapeutics in alzheimer’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603563/ https://www.ncbi.nlm.nih.gov/pubmed/36292947 http://dx.doi.org/10.3390/ijms232012092 |
work_keys_str_mv | AT campospenavictoria amyloidblipidmetabolismbasalcholinergicsystemandtherapeuticsinalzheimersdisease AT pichardorojaspavel amyloidblipidmetabolismbasalcholinergicsystemandtherapeuticsinalzheimersdisease AT sanchezbarbosatalia amyloidblipidmetabolismbasalcholinergicsystemandtherapeuticsinalzheimersdisease AT ortizislasemma amyloidblipidmetabolismbasalcholinergicsystemandtherapeuticsinalzheimersdisease AT rodriguezperezcitlaliekaterina amyloidblipidmetabolismbasalcholinergicsystemandtherapeuticsinalzheimersdisease AT montespedro amyloidblipidmetabolismbasalcholinergicsystemandtherapeuticsinalzheimersdisease AT ramospalaciosgerardo amyloidblipidmetabolismbasalcholinergicsystemandtherapeuticsinalzheimersdisease AT silvaadayadaniela amyloidblipidmetabolismbasalcholinergicsystemandtherapeuticsinalzheimersdisease AT valenciaquintanarafael amyloidblipidmetabolismbasalcholinergicsystemandtherapeuticsinalzheimersdisease AT cernacortesjorgefrancisco amyloidblipidmetabolismbasalcholinergicsystemandtherapeuticsinalzheimersdisease AT toralriosdanira amyloidblipidmetabolismbasalcholinergicsystemandtherapeuticsinalzheimersdisease |